New guidelines for the prevention, diagnosis and treatment of hepatocellular carcinoma
The IDIBAPS researcher Josep M. Llovet has participated in the new American AASLD guidelines for the treatment of hepatocellular carcinoma, the most1
The IDIBAPS researcher Josep M. Llovet has participated in the new American AASLD guidelines for the treatment of hepatocellular carcinoma, the most1
On Monday, March 13, the Spanish Association Against Cancer (AECC) announced the 2022 AECC Cancer Research Grants.
The list, published by Clarivate Analytics, identifies the most influential experts, who are among the 1% most highly cited in their speciality in di1
In an important breakthrough in precision medicine and for the approval of cost-effective treatments, the expression of eleven genes is found to make1
Researchers at the Hospital Clínic-IDIBAPS and the University of Barcelona have published a review article in the journal Nature Cancer in which they1
Immunotherapy has revolutionized the treatment of hepatocellular carcinoma. Researchers from the Hospital Clínic-IDIBAPS have published a review in t1
Researchers at IDIBAPS have led a study, published in the journal Gastroenterology, in which they analyzed the clinical trials published in the past1
IDIBAPS researchers have drafted a molecular map of the most common type of liver cancer, hepatocellular carcinoma, when the origin is fatty liver di1
An article published in the journal Nature suggests that immunotherapy is effective in patients with HCC of viral origin but does not increase surviv1
Clínic-IDIBAPS researchers have coordinated two review articles on hepatocellular carcinoma (HCC), the most common type of liver cancer, in which the1